Leerink Starts Larimar Therapeutics (LRMR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Price: $2.76 --0%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 30 | New: 5
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 30 | New: 5
Join SI Premium – FREE
Leerink analyst Joseph Schwartz initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Outperform rating and a price target of $13.00.
For an analyst ratings summary and ratings history on Larimar Therapeutics click here. For more ratings news on Larimar Therapeutics click here.
Shares of Larimar Therapeutics closed at $3.92 yesterday.
You May Also Be Interested In
- Citi initiates ATI Inc. coverage with Buy rating, $229 target
- Goldman Sachs Downgrades Regis Resources Ltd. (RRL:AU) (RGRNF) to Sell
- H.C. Wainwright Starts Insmed (INSM) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
